Pfizer's Q2 Earnings Reveal Strong Revenue Growth and Increased Guidance for 2024

Tuesday, 30 July 2024, 12:56
Pfizer has announced its Q2 results, revealing an adjusted EPS of $0.60, surpassing analysts' expectations of $0.46. The company achieved sales of $13.28 billion, which was bolstered by acquired products and new launches, despite a dip in revenue from Comirnaty. Looking ahead, Pfizer has increased its 2024 revenue forecast to between $59.5 billion and $62.5 billion, with an anticipated EPS of $2.45 to $2.65. This performance marks the first revenue growth for Pfizer since the peak COVID revenue in 2022.
Benzinga
Pfizer's Q2 Earnings Reveal Strong Revenue Growth and Increased Guidance for 2024

Pfizer's Q2 Earnings Overview

Pfizer has reported its Q2 earnings, marking a significant milestone in revenue growth. The company achieved an adjusted EPS of $0.60, which exceeds the consensus estimate of $0.46.

Sales Performance

Sales for the quarter reached $13.28 billion, driven by its acquired products and new product launches. This growth came despite a decline in revenue from its COVID-19 vaccine, Comirnaty.

Revised Guidance for 2024

  • Pfizer has revised its revenue guidance for 2024.
  • The new forecast is between $59.5 billion and $62.5 billion.
  • Expected EPS for 2024 is between $2.45 and $2.65.

This latest performance indicates a promising trajectory for Pfizer as it moves beyond the pandemic's peak revenue days.

This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.

Related posts

Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe